Goserelin

Base Information

• Chemical Name: Goserelin
• CAS No.: 65807-02-5
• Deprecated CAS: 70280-59-0
• Molecular Formula: C59H84N18O14
• Molecular Weight: 1269.41
• Hs Code.: 3504009000
• European Community (EC) Number: 686-281-6
• UNII: 0F65R8P09N
• DSSTox Substance ID: DTXSID7048297
• Nikkaji Number: J34.701I
• Wikipedia: Goserelin
• Wikidata: Q1992653
• NCI Thesaurus Code: C1374
• RXCUI: 50610
• Pharos Ligand ID: MZ12Z8D3WF77
• Metabolomics Workbench ID: 42571
• ChEMBL ID: CHEMBL1201247
• Mol file: 65807-02-5.mol

Synonyms:Acetate, Goserelin;Goserelin;Goserelin Acetate;ICI 118630;ICI-118630;ICI118630;Zoladex

Chemical Property of Goserelin

Chemical Property:

• Appearance/Colour: white solid
• Refractive Index: 1.692
• PKA: 9.82±0.15(Predicted)
• PSA: 493.39000
• Density: 1.5 g/cm³
• LogP: 2.78000
• Storage Temp.: −20°C
• Solubility.: H2O: 20 mg/mL, clear, colorless
• XLogP3: -1.5
• Hydrogen Bond Donor Count: 17
• Hydrogen Bond Acceptor Count: 16
• Rotatable Bond Count: 32
• Exact Mass: 1268.64143943
• Heavy Atom Count: 91
• Complexity: 2560

Purity/Quality:

98% ^*data from raw suppliers

Goserelin ^*data from reagent suppliers

Safty Information:

• Safety Statements: 22-24/25

MSDS Files:

SDS file from LookChem

Useful:

• Drug Classes: Antineoplastic Agents
• Canonical SMILES: CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6
• Isomeric SMILES: CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6
• Recent ClinicalTrials: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
• Recent EU Clinical Trials: Short versus long-term androgen deprivation therapy combined with salvage radiotherapy in prostate cancer patients with biochemical recurrence after prostatectomy: a multicentre phase III randomised controlled trial
• Recent NIPH Clinical Trials: Amcenestrant (SAR439859) plus palbociclib as first line therapy for patients with ER(+) HER2(-) advanced breast cancer
• Description: Goserelin is an analog of luteinizing hormone-releasing hormone (LHRH) useful in the treatment of malignancies responsive to hormonal manipulation. Administered parenterally in a biodegradable depot, goserelin is reportedly as effective as orchidectomy and oophorectomy in patients with advanced prostate carcinoma and pre-menopausal breast cancer.
• Uses: Goserelin USP (Zoladex) is used to treat Prostatic carcinoma. Labelled Goserelin (G767500). Synthetic peptide agonist analog of LH-RH. Antineoplastic (hormonal). Labeled Goserelin, intended for use as an internal standard for the quantification of Goserelin by GC- or LC-mass spectrometry.
• Therapeutic Function: Antineoplastic, Antitumor
• Clinical Use: Synthetic decapeptide analogue of LHRH: Treatment of advanced prostate cancer, breast cancer, endometriosis and endometrial thinning and uterine fibroids
• Drug interactions: Potentially hazardous interactions with other drugs None known